Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop

Vaccine

Volumn 34, Issue 41, 2016, Pages 4843-4849

  Roberts, Jeffrey N ^a   Graham, Barney S ^b   Karron, Ruth A ^c   Munoz, Flor M ^d   Falsey, Ann R ^e   Anderson, Larry J ^f   Marshall, V ^a   Kim, Sonnie ^b   Beeler, Judy A ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Bronchitis; Clinical trials; Elderly; Human challenge; Infants; Maternal immunization; Neutralization; RSV; Subunit vaccine; Vaccination; Vaccine vector; Vaccine enhanced illness; Wheezing

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE; SUBUNIT VACCINE; VIRUS VECTOR;

ASSAY; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; INFANT DISEASE; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; SCIENTIST; VIRUS NEUTRALIZATION; WORKSHOP; AGED; ANIMAL; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MARYLAND; MEDICAL RESEARCH; ORGANIZATION; PRESCHOOL CHILD; UNITED STATES;

AGED; ANIMALS; BIOMEDICAL RESEARCH; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; FEMALE; HUMANS; INFANT; MARYLAND; NATIONAL INSTITUTES OF HEALTH (U.S.); PREGNANCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84990062973     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.07.057     Document Type: Conference Paper

References (40)

1. [1] Johnson, J.E., Gonzales, R.A., Olson, S.J., Wright, P.F., Graham, B.S., The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20:1 (2007), 108–119.
2. [2] Peebles, R.S. Jr., Graham, B.S., Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc 2:2 (2005), 110–115.
3. [3] Nair, H., Nokes, D.J., Gessner, B.D., Dherani, M., Madhi, S.A., Singleton, R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:9725 (2010), 1545–1555.
4. [4] Shay, D.K., Holman, R.C., Newman, R.D., Liu, L.L., Stout, J.W., Anderson, L.J., Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 282:15 (1999), 1440–1446.
5. [5] Glezen, W.P., Taber, L.H., Frank, A.L., Kasel, J.A., Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140:6 (1986), 543–546.
6. [6] Kutsaya, A., Teros-Jaakkola, T., Kakkola, L., Toivonen, L., Peltola, V., Waris, M., et al. Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life. Epidemiol Infect, 1–12, 2016.
7. [7] Falsey, A.R., Hennessey, P.A., Formica, M.A., Cox, C., Walsh, E.E., Respiratory syncytial virus infection in elderly and high-risk adults. New Engl J Med 352:17 (2005), 1749–1759.
8. [8] Kim, H.W., Canchola, J.G., Brandt, C.D., Pyles, G., Chanock, R.M., Jensen, K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:4 (1969), 422–434.
9. [9] Acosta, P.L., Caballero, M.T., Polack, F.P., Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol 23:3 (2016), 189–195.
10. [10] Graham, B.S., Vaccines against respiratory syncytial virus: the time has finally come. Vaccine 34:30 (2016), 3535–3541.
11. [11] Ngwuta, J.O., Chen, M., Modjarrad, K., Joyce, M.G., Kanekiyo, M., Kumar, A., et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med, 7(309), 2015, 309ra162.
12. [12] Siber, G.R., Leombruno, D., Leszczynski, J., McIver, J., Bodkin, D., Gonin, R., et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 169:6 (1994), 1368–1373.
13. [13] Groothuis, J.R., Simoes, E.A., Levin, M.J., Hall, C.B., Long, C.E., Rodriguez, W.J., et al., The Respiratory Syncytial Virus Immune Globulin Study Group. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. New Engl J Med 329:21 (1993), 1524–1530.
14. [14] The IMpact-RSV Study Group, Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:3 Pt 1 (1998), 531–537.
15. [15] Habibi, M.S., Jozwik, A., Makris, S., Dunning, J., Paras, A., DeVincenzo, J.P., et al. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med 191:9 (2015), 1040–1049.
16. [16] Wright, P.F., Karron, R.A., Belshe, R.B., Shi, J.R., Randolph, V.B., Collins, P.L., et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25:42 (2007), 7372–7378.
17. [17] Modjarrad, K., Giersing, B., Kaslow, D.C., Smith, P.G., Moorthy, V.S., WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23–24 March 2015. Vaccine, 2015.
18. [18] Haynes, A.K., Prill, M.M., Iwane, M.K., Gerber, S.I., Centers for Disease C, Prevention. Respiratory syncytial virus–United States, July 2012–June 2014. MMWR Morb Mortal Wkly Rep 63:48 (2014), 1133–1136.
19. [19] Behrendt, C.E., Decker, M.D., Burch, D.J., Watson, P.H., International RSV Study Group. International variation in the management of infants hospitalized with respiratory syncytial virus. Eur J Pediatr 157:3 (1998), 215–220.
20. [20] Simoes, E.A., Carbonell-Estrany, X., Guilbert, T., Mansbach, J.M., Piedra, P.A., Ramilo, O., et al. Clinical endpoints for respiratory syncytial virus prophylaxis trials in infants and children in high and middle income countries. Pediat Infect Dis J 34:10 (2015), 1086–1092.
21. [21] Regnier, S.A., Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine. Vaccine 31:40 (2013), 4347–4354.
22. [22] Roberts, J.N., Gruber, M.F., Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy. Vaccine 33:8 (2015), 966–972.
23. [23] Ralston, S.L., Lieberthal, A.S., Meissner, H.C., Alverson, B.K., Baley, J.E., Gadomski, A.M., et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 134:5 (2014), e1474–e1502.
24. [24] Nokes, D.J., Ngama, M., Bett, A., Abwao, J., Munywoki, P., English, M., et al. Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance. Clin Infect Dis 49:9 (2009), 1341–1349.
25. [25] Simoes, E.A., Carbonell-Estrany, X., Rieger, C.H., Mitchell, I., Fredrick, L., Groothuis, J.R., The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 126:2 (2010), 256–262.
26. [26] Blanken, M.O., Rovers, M.M., Bont, L., Respiratory syncytial virus and recurrent wheeze. New Engl J Med 369:8 (2013), 782–783.
27. [27] O'Brien, K.L., Chandran, A., Weatherholtz, R., Jafri, H.S., Griffin, M.P., Bellamy, T., et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis 15:12 (2015), 1398–1408.
28. [28] Amirthalingam, G., Andrews, N., Campbell, H., Ribeiro, S., Kara, E., Donegan, K., et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 384:9953 (2014), 1521–1528.
29. [29] Zaman, K., Roy, E., Arifeen, S.E., Rahman, M., Raqib, R., Wilson, E., et al. Effectiveness of maternal influenza immunization in mothers and infants. New Engl J Med 359:15 (2008), 1555–1564.
30. [30] Chu, H.Y., Steinhoff, M.C., Magaret, A., Zaman, K., Roy, E., Langdon, G., et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis 210:10 (2014), 1582–1589.
31. [31] Munoz, F.M., Piedra, P.A., Glezen, W.P., Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21:24 (2003), 3465–3467.
32. [32] Munoz, F.M., Sheffield, J.S., Beigi, R.H., Read, J.S., Swamy, G.K., Jevaji, I., et al. Research on vaccines during pregnancy: protocol design and assessment of safety. Vaccine 31:40 (2013), 4274–4279.
33. [33] Sheffield, J.S., Munoz, F.M., Beigi, R.H., Rasmussen, S.A., Edwards, K.M., Read, J.S., et al. Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments. Vaccine 31:40 (2013), 4264–4273.
34. [34] Glenn, G.M., Fries, L.F., Thomas, D.N., Smith, G., Kpamegan, E., Lu, H., et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 213:3 (2016), 411–422.
35. [35] Walsh, E.E., Falsey, A.R., Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 190:2 (2004), 373–378.
36. [36] Walsh, E.E., Peterson, D.R., Falsey, A.R., Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 189:2 (2004), 233–238.
37. [37] Walsh, E.E., Peterson, D.R., Kalkanoglu, A.E., Lee, F.E., Falsey, A.R., Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis 207:9 (2013), 1424–1432.
38. [38] Curtis, S.J., Ottolini, M.G., Porter, D.D., Prince, G.A., Age-dependent replication of respiratory syncytial virus in the cotton rat. Exp Biol Med (Maywood) 227:9 (2002), 799–802.
39. [39] Boukhvalova, M.S., Yim, K.C., Kuhn, K.H., Hemming, J.P., Prince, G.A., Porter, D.D., et al. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment. J Infect Dis 195:4 (2007), 511–518.
40. [40] Qualification Process for Drug Development Tools, < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf>.